Thus, based on these findings, pharmacological antagonism aimed at tempering GnRH–LH secretion is an attractive therapeutic strategy to restore ovulation and fertility in women with PCOS characterized by high LH levels (> 75% of women with PCOS), given the fact that GnRH antagonists are already used in the clinic in adult subjects without reported deleterious side effects. This evidence concerns the gene GNRH1 and polycystic ovary syndrome.